抽象的な

Applying precision medicine approach to metastatic castration-resistant prostate cancer: urgent education need on genomic oncology

Jue Wang

Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. As a result of advances in genomic sequencing technology, “next-generation sequencing” (NGS) is increasingly incorporated into clinical trials and routine oncology clinical practice. Molecular profiling of mCRPC can be a valuable way of defining molecular alterations that might contribute to optimal treatments while reduce risk of adverse effects. To effectively apply cutting edge research to daily patient care, oncologists must grasp the fundamentals of genomic oncology, molecular testing and interpretation. There is an urgent need for health professional education to allow implementation of these novel precision medicine tools.